Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II/III Intravitreal Triamcinolone for Treatment of Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment

NCT00167518 is registered in ClinicalTrials.gov with University of Sydney as lead sponsor.

NCT NCT00167518
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00167518 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II/III Intravitreal Triamcinolone for Treatment of Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment
Lead sponsor
University of Sydney
Phase
Phase 2/3
Overall status
Completed
Start date
March 31, 2002
Completion date
April 30, 2005
Enrollment
70
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular oedema